bioAffinity Technologies

bioAffinity Technologies ROA

The Return on Assets (ROA) of bioAffinity Technologies (BIAF) as of Oct 22, 2026 is -136.03 %. In the previous year, Return on Assets (ROA) was -138.79 % — a change of -1.99% (higher).

ROA

-136.03 %

YoY

-1.99%

Last updated:

In 2025, bioAffinity Technologies's return on assets (ROA) was -136.03 %, a -1.99% increase from the -138.79 % ROA in the previous year.

The bioAffinity Technologies ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2019
-502.04 USD
Jan 1, 2020
-4,992.09 USD
Jan 1, 2021
-435.31 USD
Jan 1, 2022
-66.94 USD
Jan 1, 2023
-96.54 USD
Jan 1, 2024
-138.79 USD
Jan 1, 2025
-136.03 USD
The bioAffinity Technologies ROA history
YEARROAYoY
-136.03 %-1.99%
-138.79 %+43.76%
-96.54 %+44.23%
-66.94 %-84.62%
-435.31 %-91.28%
-4,992.09 %+894.36%
-502.04 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

bioAffinity Technologies Stock analysis

What does bioAffinity Technologies do? bioAffinity Technologies, Inc. generates revenue through the development of noninvasive diagnostic tests and cancer therapeutics. The company's lead product, CyPath Lung, targets early-stage lung cancer detection without invasive procedures. Through its subsidiary OncoSelect Therapeutics, LLC, it advances cancer therapeutics that selectively target cancer cells. The company focuses on expanding its platform to develop tests for various cancers and potentially other diseases, aiming to address unmet medical needs in oncology. The firm's primary buyers are healthcare providers and medical institutions seeking noninvasive diagnostic solutions for early cancer detection. These institutions purchase CyPath Lung for screening and diagnostic purposes, particularly for lung cancer cases. The company's therapeutic pipeline, developed via OncoSelect Therapeutics, targets healthcare and pharmaceutical partners interested in selective cancer treatments. bioAffinity's development-stage focus means it currently relies on research and development funding rather than commercial sales, with its IPO in 2022 supporting further platform expansion. bioAffinity Technologies, Inc. operates in the medical technology sector, targeting early-stage cancer diagnosis and treatment. Its products are designed to detect cancer through noninvasive means, reducing patient discomfort and enabling earlier intervention. The company's subsidiary OncoSelect Therapeutics drives the development of targeted cancer therapeutics, focusing on selective targeting of diseased cell populations. This approach positions bioAffinity to address significant unmet needs in oncology, particularly for lung cancer diagnostics and therapeutics. bioAffinity Technologies is one of the most popular companies on Eulerpool.

ROA Details

Understanding bioAffinity Technologies's Return on Assets (ROA)

bioAffinity Technologies's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing bioAffinity Technologies's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider bioAffinity Technologies's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in bioAffinity Technologies’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about bioAffinity Technologies stock

Return on Assets (ROA) of bioAffinity Technologies is -136.03 % in 2025.

Return on Assets (ROA) of bioAffinity Technologies changed from -138.79 % to -136.03 %, representing a -1.99% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) bioAffinity Technologies since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s bioAffinity Technologies with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — bioAffinity Technologies

All Key Metrics — bioAffinity Technologies